Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK/TGF-β1/Smad Signaling
The Tohoku Journal of Experimental Medicine · 2023 · 261 (4) · 257-265
DOI: 10.1620/tjem.2023.j050 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2023. Verfasst von Jialuo Cai und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hunan University of Chinese Medicine. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Improving hepatic glucose and lipid metabolisms is an important strategy to treat type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease (T2DM-NAFLD). Silybin (SLB) has the potential hepatoprotection, while its oral bioavailability is poor. This study aims to investigate the functional role and mechanism of liposomal SLB in modulating glucose/lipid metabolism in T2DM-NAFLD. SLB was prepared by thin film dispersion method and characterized using dynamic light scattering, scanning electron microscope, high performance liquid chromatography and zeta potential analyzer. A rat model of T2DM-NAFLD was used to determine the role of liposomal SLB in regulating glycolipid metabolism and hepatic damage. Rat primary hepatocytes were used to demonstrate the hepatoprotection mechanism of liposomal SLB. The encapsulation efficiency was more than 80%, which showed the average particle size of 119.76 nm. Also, the average Zeta potential was -4.76 mV. These liposomes were spherical. In rats with T2DM-NAFLD, liposomal SLB alleviated insulin resistance and lipid metabolism, thereby improving hepatic lipid accumulation, inflammation and fibrosis. Besides, liposomal SLB elevated AMPK phosphorylation, and decreased collagen I/III, α-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1) and the phosphorylation of Smad2/3. In hepatocyte model, compound C partially reversed the effects of liposomal SLB on cell viability, glycolipid metabolism and AMPK/TGF-β1/Smad pathway activation. Liposomal SLB ameliorates hepatic glucose and lipid metabolisms in T2DM-NAFLD via activating AMPK/TGF-β1/Smad pathway, providing an efficient strategy for treating T2DM-NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hunan University of Chinese Medicine.
- Preventive Treatment of Disease Center, The First Hospital of Hunan University of Chinese Medicine.
- Graduate School, Hunan University of Chinese Medicine.
- Scientific Research Section, The First Hospital of Hunan University of Chinese Medicine.
- Library, Hunan University of Chinese Medicine.
- Party Committee, Hunan University of Chinese Medicine.
Zitieren
APA
Cai, J., Zhu, Y., Li, X., Deng, G., Han, Y., Yuan, F., Yi, G., & Xia, X. (2023). Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK/TGF-β1/Smad Signaling. The Tohoku Journal of Experimental Medicine, 261(4), 257-265. https://doi.org/10.1620/tjem.2023.j050
Vancouver
Cai J, Zhu Y, Li X, Deng G, Han Y, Yuan F, et al. Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK/TGF-β1/Smad Signaling. The Tohoku Journal of Experimental Medicine. 2023;261(4):257-265. doi:10.1620/tjem.2023.j050
BibTeX
@article{Cai2023,
author = {Cai, Jialuo and Zhu, Yilin and Li, Xiaoping and Deng, Guiming and Han, Yuanshan and Yuan, Feiyun and Yi, Gangqiang and Xia, Xinhua},
title = {Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK/TGF-β1/Smad Signaling},
journal = {The Tohoku Journal of Experimental Medicine},
year = {2023},
volume = {261},
number = {4},
pages = {257--265},
doi = {10.1620/tjem.2023.j050}
}
EUVIMED